Aclaris Therapeutics, Inc. Research and Development Expense
Aclaris Therapeutics, Inc. (ACRS) reported Research and Development Expense of $18.07 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-06
- Aclaris Therapeutics, Inc. research and development expense for the quarter ending 2026-06-30 was $18.07M, a 57.80% increase year-over-year.
- Aclaris Therapeutics, Inc. research and development expense for the quarter ending 2026-03-31 was $15.66M, a 35.16% increase year-over-year.
- Aclaris Therapeutics, Inc. research and development expense for the quarter ending 2025-12-31 was $16.58M, a 83.74% increase year-over-year.
- Aclaris Therapeutics, Inc. research and development expense for the quarter ending 2025-09-30 was $13.03M, a 118.74% increase year-over-year.
- Aclaris Therapeutics, Inc. research and development expense for fiscal 2025 was $52.65M, a 56.75% increase from fiscal 2024.
- Aclaris Therapeutics, Inc. research and development expense for fiscal 2024 was $33.59M, a 65.86% decline from fiscal 2023.
- Aclaris Therapeutics, Inc. research and development expense for fiscal 2023 was $98.38M, a 26.44% increase from fiscal 2022.
- Aclaris Therapeutics, Inc. research and development expense for fiscal 2022 was $77.81M, a 77.60% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $18.07M 10-Q · filed 2026-08-06 | $33.72M 10-Q · filed 2026-08-06 | $50.31M derived: sum of 3 quarters · filed 2026-08-06 | $63.34M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | $15.66M 10-Q · filed 2026-05-07 | $32.24M derived: sum of 2 quarters · filed 2026-05-07 | $45.27M derived: sum of 3 quarters · filed 2026-05-07 | $56.72M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-12-31 | $16.58M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $29.61M derived: sum of 2 quarters · filed 2026-02-26 | $41.06M derived: sum of 3 quarters · filed 2026-08-06 | $52.65M 10-K · filed 2026-02-26 | ||||
| 2025-09-30 | $13.03M 10-Q · filed 2025-11-06 | $24.48M derived: sum of 2 quarters · filed 2026-08-06 | $36.06M 10-Q · filed 2025-11-06 | $45.09M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | $11.45M 10-Q · filed 2026-08-06 | $23.03M 10-Q · filed 2026-08-06 | $32.06M derived: sum of 3 quarters · filed 2026-08-06 | $38.02M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-03-31 | $11.58M 10-Q · filed 2026-05-07 | $20.61M derived: sum of 2 quarters · filed 2026-05-07 | $26.57M derived: sum of 3 quarters · filed 2026-05-07 | $35.33M derived: sum of 4 quarters · filed 2026-05-07 | ||||
| 2024-12-31 | $9.03M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $14.98M derived: sum of 2 quarters · filed 2026-02-26 | $23.74M derived: sum of 3 quarters · filed 2026-02-26 | $33.59M 10-K · filed 2026-02-26 | ||||
| 2024-09-30 | $5.96M 10-Q · filed 2025-11-06 | $14.71M derived: sum of 2 quarters · filed 2025-11-06 | $24.56M 10-Q · filed 2025-11-06 | $51.21M derived: sum of 4 quarters · filed 2025-11-06 | ||||
| 2024-06-30 | $8.76M 10-Q · filed 2025-08-07 | $18.60M 10-Q · filed 2025-08-07 | $45.25M derived: sum of 3 quarters · filed 2025-08-07 | $69.13M derived: sum of 4 quarters · filed 2025-08-07 | ||||
| 2024-03-31 | $9.85M 10-Q · filed 2025-05-08 | $36.49M derived: sum of 2 quarters · filed 2025-05-08 | $60.37M derived: sum of 3 quarters · filed 2025-05-08 | $85.64M derived: sum of 4 quarters · filed 2025-05-08 | ||||
| 2023-12-31 | $26.65M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $50.52M derived: sum of 2 quarters · filed 2025-02-27 | $75.80M derived: sum of 3 quarters · filed 2025-02-27 | $98.38M 10-K · filed 2025-02-27 | ||||
| 2023-09-30 | $23.88M 10-Q · filed 2024-11-06 | $49.15M derived: sum of 2 quarters · filed 2024-11-06 | $71.74M 10-Q · filed 2024-11-06 | $92.81M derived: sum of 4 quarters · filed 2024-11-06 | ||||
| 2023-06-30 | $25.27M 10-Q · filed 2024-08-07 | $47.86M 10-Q · filed 2024-08-07 | $68.93M derived: sum of 3 quarters · filed 2024-08-07 | $92.59M derived: sum of 4 quarters · filed 2024-08-07 | ||||
| 2023-03-31 | $22.59M 10-Q · filed 2024-05-07 | $43.66M derived: sum of 2 quarters · filed 2024-05-07 | $67.31M derived: sum of 3 quarters · filed 2024-05-07 | $86.09M derived: sum of 4 quarters · filed 2024-05-07 | ||||
| 2022-12-31 | $21.07M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $44.73M derived: sum of 2 quarters · filed 2024-02-27 | $63.51M derived: sum of 3 quarters · filed 2024-02-27 | $77.81M 10-K · filed 2024-02-27 | ||||
| 2022-09-30 | $23.66M 10-Q · filed 2023-11-06 | $42.44M derived: sum of 2 quarters · filed 2023-11-06 | $56.74M 10-Q · filed 2023-11-06 | $70.84M derived: sum of 4 quarters · filed 2024-02-27 | ||||
| 2022-06-30 | $18.78M 10-Q · filed 2023-08-07 | $33.09M 10-Q · filed 2023-08-07 | $47.19M derived: sum of 3 quarters · filed 2024-02-27 | $61.16M derived: sum of 4 quarters · filed 2024-02-27 | ||||
| 2022-03-31 | $14.31M 10-Q · filed 2023-05-08 | $28.41M derived: sum of 2 quarters · filed 2024-02-27 | $42.38M derived: sum of 3 quarters · filed 2024-02-27 | $50.28M derived: sum of 4 quarters · filed 2024-02-27 | ||||
| 2021-12-31 | $14.10M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $28.08M derived: sum of 2 quarters · filed 2024-02-27 | $35.98M derived: sum of 3 quarters · filed 2024-02-27 | $43.81M 10-K · filed 2024-02-27 | ||||
| 2021-09-30 | $13.98M 10-Q · filed 2022-11-08 | $21.87M derived: sum of 2 quarters · filed 2022-11-08 | $29.71M 10-Q · filed 2022-11-08 | $38.67M derived: sum of 4 quarters · filed 2023-02-23 | ||||
| 2021-06-30 | $7.90M 10-Q · filed 2022-08-03 | $15.73M 10-Q · filed 2022-08-03 | $24.69M derived: sum of 3 quarters · filed 2023-02-23 | $30.93M derived: sum of 4 quarters · filed 2023-02-23 | ||||
| 2021-03-31 | $7.84M 10-Q · filed 2022-05-10 | $16.79M derived: sum of 2 quarters · filed 2023-02-23 | $23.03M derived: sum of 3 quarters · filed 2023-02-23 | $29.50M derived: sum of 4 quarters · filed 2023-02-23 | ||||
| 2020-12-31 | $8.96M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $15.20M derived: sum of 2 quarters · filed 2023-02-23 | $21.66M derived: sum of 3 quarters · filed 2023-02-23 | $29.34M 10-K · filed 2023-02-23 | $31.73M 10-K · filed 2021-02-25 | |||
| 2020-09-30 | $6.24M 10-Q · filed 2021-11-02 | $6.87M 10-Q · filed 2020-11-04 | $12.71M derived: sum of 2 quarters · filed 2021-11-02 | $20.38M 10-Q · filed 2021-11-02 | $22.77M 10-Q · filed 2020-11-04 | $31.21M derived: sum of 4 quarters · filed 2022-02-24 | ||
| 2020-06-30 | $6.47M 10-Q · filed 2021-08-05 | $14.14M 10-Q · filed 2021-08-05 | $15.91M 10-Q · filed 2020-08-07 | $24.97M derived: sum of 3 quarters · filed 2022-02-24 | $41.16M derived: sum of 4 quarters · filed 2022-02-24 | |||
| 2020-03-31 | $7.68M 10-Q · filed 2021-05-07 | $9.44M 10-Q · filed 2020-05-07 | $18.51M derived: sum of 2 quarters · filed 2022-02-24 | $34.69M derived: sum of 3 quarters · filed 2022-02-24 | $52.21M derived: sum of 4 quarters · filed 2022-02-24 | |||
| 2019-12-31 | $10.83M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $27.01M derived: sum of 2 quarters · filed 2022-02-24 | $44.53M derived: sum of 3 quarters · filed 2022-02-24 | $64.17M 10-K · filed 2022-02-24 | $64.90M 10-K · filed 2020-02-25 | |||
| 2019-09-30 | $16.18M 10-Q · filed 2020-11-04 | $33.70M derived: sum of 2 quarters · filed 2020-11-04 | $53.33M 10-Q · filed 2020-11-04 | $72.70M derived: sum of 4 quarters · filed 2021-02-25 | ||||
| 2019-06-30 | $17.52M 10-Q · filed 2020-08-07 | $17.62M 10-Q · filed 2019-08-08 | $37.16M 10-Q · filed 2020-08-07 | $37.54M 10-Q · filed 2019-08-08 | $56.52M derived: sum of 3 quarters · filed 2021-02-25 | $71.71M derived: sum of 4 quarters · filed 2021-02-25 | ||
| 2019-03-31 | $19.64M 10-Q · filed 2020-05-07 | $19.92M 10-Q · filed 2019-05-08 | $39.00M derived: sum of 2 quarters · filed 2021-02-25 | $54.19M derived: sum of 3 quarters · filed 2021-02-25 | $68.17M derived: sum of 4 quarters · filed 2021-02-25 | |||
| 2018-12-31 | $19.36M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $34.55M derived: sum of 2 quarters · filed 2021-02-25 | $48.53M derived: sum of 3 quarters · filed 2021-02-25 | $60.84M 10-K · filed 2021-02-25 | $63.01M 10-K · filed 2019-03-18 | |||
| 2018-09-30 | $15.19M 10-Q · filed 2019-11-07 | $15.93M 10-Q · filed 2018-11-06 | $29.17M derived: sum of 2 quarters · filed 2019-11-07 | $41.48M 10-Q · filed 2019-11-07 | $43.47M 10-Q · filed 2018-11-06 | $51.98M derived: sum of 4 quarters · filed 2020-02-25 | ||
| 2018-06-30 | $13.98M 10-Q · filed 2019-08-08 | $27.59M 10-Q · filed 2019-08-08 | $36.79M derived: sum of 3 quarters · filed 2020-02-25 | $47.66M derived: sum of 4 quarters · filed 2020-02-25 | ||||
| 2018-03-31 | $13.61M 10-Q · filed 2019-05-08 | $22.81M derived: sum of 2 quarters · filed 2020-02-25 | $33.67M derived: sum of 3 quarters · filed 2020-02-25 | $41.64M derived: sum of 4 quarters · filed 2020-02-25 | ||||
| 2017-12-31 | $9.20M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $20.07M derived: sum of 2 quarters · filed 2020-02-25 | $28.03M derived: sum of 3 quarters · filed 2020-02-25 | $35.80M 10-K · filed 2020-02-25 | $39.79M 10-K · filed 2018-03-12 | |||
| 2017-09-30 | $10.86M 10-Q · filed 2018-11-06 | $18.83M derived: sum of 2 quarters · filed 2018-11-06 | $26.60M 10-Q · filed 2018-11-06 | $33.54M derived: sum of 4 quarters · filed 2019-03-18 | ||||
| 2017-06-30 | $7.96M 10-Q · filed 2018-08-03 | $15.74M 10-Q · filed 2018-08-03 | $22.68M derived: sum of 3 quarters · filed 2019-03-18 | $29.84M derived: sum of 4 quarters · filed 2019-03-18 | ||||
| 2017-03-31 | $7.77M 10-Q · filed 2018-05-08 | $14.71M derived: sum of 2 quarters · filed 2019-03-18 | $21.88M derived: sum of 3 quarters · filed 2019-03-18 | $31.71M derived: sum of 4 quarters · filed 2019-03-18 | ||||
| 2016-12-31 | $6.94M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18 | $14.11M derived: sum of 2 quarters · filed 2019-03-18 | $23.94M derived: sum of 3 quarters · filed 2019-03-18 | $33.48M 10-K · filed 2019-03-18 | ||||
| 2016-09-30 | $7.16M 10-Q · filed 2017-11-07 | $17.00M derived: sum of 2 quarters · filed 2017-11-07 | $26.53M 10-Q · filed 2017-11-07 | $28.93M derived: sum of 4 quarters · filed 2018-03-12 | ||||
| 2016-06-30 | $9.84M 10-Q · filed 2017-08-08 | $19.37M 10-Q · filed 2017-08-08 | $21.77M derived: sum of 3 quarters · filed 2018-03-12 | $31.18M derived: sum of 4 quarters · filed 2018-03-12 | ||||
| 2016-03-31 | $9.54M 10-Q · filed 2017-05-09 | $11.94M derived: sum of 2 quarters · filed 2018-03-12 | $21.34M derived: sum of 3 quarters · filed 2018-03-12 | $23.14M derived: sum of 4 quarters · filed 2018-03-12 | ||||
| 2015-12-31 | $2.40M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $11.81M derived: sum of 2 quarters · filed 2018-03-12 | $13.60M derived: sum of 3 quarters · filed 2018-03-12 | $15.34M 10-K · filed 2018-03-12 | ||||
| 2015-09-30 | $9.41M 10-Q · filed 2016-11-03 | $9.41M 10-Q · filed 2015-12-03 | $11.20M derived: sum of 2 quarters · filed 2016-11-03 | $12.94M 10-Q · filed 2016-11-03 | $14.99M derived: sum of 4 quarters · filed 2017-03-15 | |||
| 2015-06-30 | $1.79M 10-Q · filed 2016-08-11 | $3.53M 10-Q · filed 2016-08-11 | $5.58M derived: sum of 3 quarters · filed 2017-03-15 | $7.68M derived: sum of 4 quarters · filed 2017-03-15 | ||||
| 2015-03-31 | $1.74M 10-Q · filed 2016-05-11 | $3.79M derived: sum of 2 quarters · filed 2017-03-15 | $5.89M derived: sum of 3 quarters · filed 2017-03-15 | |||||
| 2014-12-31 | $2.05M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-15 | $4.15M derived: sum of 2 quarters · filed 2017-03-15 | $6.51M 10-K · filed 2017-03-15 | |||||
| 2014-09-30 | $2.10M 10-Q · filed 2015-12-03 | $4.45M 10-Q · filed 2015-12-03 | ||||||
| 2013-12-31 | $3.49M 10-K · filed 2016-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |